

## **Q1 2015 Results Presentation**

Uwe Röhrhoff, CEO Rainer Beaujean, CFO Duesseldorf, April 14, 2015



#### **Disclaimer**

- 1. This presentation may contain certain forward-looking statements, including assumptions, opinions and views of the Company or cited from third party sources. Various known and unknown risks, uncertainties and other factors could cause the actual results, financial position, development or performance of the Company to differ materially from the estimations expressed or implied herein.
- 2. The Company does not guarantee that the assumptions underlying such forward-looking statements are free from errors nor does the Company accept any responsibility for the future accuracy of the opinions expressed in this presentation or the actual occurrence of the forecast development.
- 3. No representation or warranty (express or implied) is made as to, and no reliance should be placed on, any information, including projections, estimates, targets and opinions, contained herein, and no liability whatsoever is accepted as to any errors, omissions or misstatements contained herein, and, accordingly, none of the Company or any of its parent or subsidiary undertakings or any of such person's officers, directors or employees accepts any liability whatsoever arising directly or indirectly from the use of this document.




# **Review Q1 2015**


Uwe Röhrhoff, CEO





#### Q1 2015 with strong increase in earnings

#### **Key Group figures in EUR m, EPS in EUR**












#### Excellent progress with growth projects - a few examples

Cleanrooms in Peachtree City, USA



Global machine strategy for vials & ampoules



Inhaler production lines in HT, Czech Republic



New plant/cleanrooms for vials in Kosamba, India





## Financial overview Q1 2015

Rainer Beaujean, CFO



# Flattish growth in Q1 2015 resulted from soft demand – but fully in line with expectations

#### **Revenues by division**

	Q1 2015 EUR m	Q1 2014 EUR m	Growth in %	Organic growth¹ in %
Total Group	301.8	297.5	+1.4	-2.4
Plastics & Devices	137.6	135.6	+1.5	+0.3
Primary Packaging Glass	146.4	146.0	+0.2	-4.9
Life Science Research	22.8	20.3	+12.4	-1.6

<sup>1.</sup> Organic growth: At const. FX rates, excluding acquisitions, divestments and optimization of business portfolio



## P&D drives adjusted EBITDA margin expansion in Q1 2015

#### Adjusted EBITDA<sup>1</sup> by division

	Q1 2015		Q1 2014	
	EUR m	Margin in %	EUR m	Margin in %
Total Group	51.0	16.9	47.6	16.0
Plastics & Devices	25.5	18.5	21.0	15.5
Primary Packaging Glass	27.9	19.1	28.7	19.6
Life Science Research	2.8	12.1	2.5	12.2

<sup>1.</sup> Earnings before income taxes, net finance expense, amortization of fair value adjustments, extraordinary depreciation, depreciation and amortization, restructuring expenses and one-off expenses and income.



### Q1 2015: All earnings figures up quarter-over-quarter

	Q1 2015 EUR m	Q1 2014 EUR m	Growth in %
Adjusted EBITDA <sup>1</sup>	51.0	47.6	7.2
Depreciation/amortization	-26.0	-25.9	
Restructuring/one-offs	-0.4	0.0	
EBIT	24.6	21.7	13.1
Net finance expense and taxes	-11.9	-11.4	
Net income	12.7	10.3	22.8
EPS in EUR	0.35	0.29	20.7
Adjusted EPS in EUR	0.43	0.38	13.2

<sup>1.</sup> Earnings before income taxes, net finance expense, amortization of fair value adjustments, extraordinary depreciation, depreciation and amortization, restructuring expenses and one-off expenses and income.



### Strong key balance sheet and cash flow figures

	Feb 28, 2015 EUR m	Feb 28, 2014 EUR m	Change in %
Total assets	1,695.7	1,603.0	+5.8
Equity Equity ratio	623.5 36.8%	570.9 35.6%	+9.2
Net working capital <sup>1</sup> average NWC in % of LTM revenues	263.4 19.6%	228.1 18.7%	+15.5 -
	Q1 2015	Q1 2014	Change
Capex	13.9	21.7	-7.8
Cash flow from operating activities	9.7	2.9	+6.8
Operating cash flow	15.9	-1.7	+17.6
Free cash flow before financing activities	-4.2	-18.6	+14.4

<sup>1.</sup> Inventories (incl. prepayments made) and trade receivables less trade payables and payments received on account of orders.



#### Long-term financing structure with ample financial leeway

#### Comparison of debt/cash positions in EUR m





# Key takeaways Q1 2015: Strong increase in earnings and cash flow figures despite flattish revenue growth

- Increased profitability
  - ☐ Adjusted EBITDA up 7.2%
  - ☐ EBIT progressed by 13.1%
  - ☐ EPS increased by 20.7%
- Operating cash flow markedly up to EUR 15.9m

(Q1 2014: EUR -1.7m)



## **Guidance FY 2015**

Uwe Röhrhoff, CEO



# Re-iteration of Guidance FY 2015 and mid-term outlook FY 2016-2018

**Guidance FY 2015** 

Outlook FY 2016-2018

Revenues (organic growth) <sup>1</sup>	+1% to +3%; equals approx. EUR 1,300m to EUR 1,330m	+4% to +6% CAGR
Adjusted EBITDA (at const. FX) <sup>2</sup>	EUR 255m to EUR 265m	Uplift towards 21% adjusted EBITDA margin in 2018
Capex (at const. FX) <sup>2</sup>	9% to 10% of revenues	9% to 10% of revenues

<sup>1.</sup> Organic growth: At const. FX rates, excluding acquisitions, divestments and optimization of business portfolio

<sup>2.</sup> Average budgeted exchange rate assumption: EUR 1.00 = USD 1.30



## **Questions & Answers**



#### **Investor Relations & Creditor Relations contact details**

Name	Investor Relations & Creditor Relations		
Phone	+49 211 6181 257		
Fax	+49 211 6181 121		
E-mail	Gerresheimer.ir@gerresheimer.com		
IR website	www.gerresheimer.com/ir		



## GERRESHEIMER

#### Financial calendar

April 30, 2015	Annual General Meeting 2015		
July 9, 2015	Interim Report 2nd Quarter 2015		
October 8, 2015	Interim Report 3rd Quarter 2015		





Gerresheimer will become the leading global partner for enabling solutions that improve health and well-being.

Our success is driven by the passion of our people.



# **Backup**



### Development of net working capital<sup>1</sup>

	Feb 28, 2015 EUR m	Feb 28, 2014 EUR m
Inventories thereof prepayments made	213.4 7.9	199.9 <i>1</i> 9.3
Trade receivables	209.9	187.5
Trade payables	112.3	100.6
Payments received on account of orders	47.6	58.7
Net working capital in % of LTM revenues	<b>263.4</b> 20.4	<b>228.1</b> 18.0

<sup>1.</sup> Inventories (incl. prepayments made) and trade receivables less trade payables and payments received on account of orders.



## **Development of inventories**

	Feb 28, 2015 EUR m	Feb 28, 2014 EUR m
Raw materials, consumables and supplies	53.2	51.8
Work in progress	26.1	22.6
Finished goods and merchandise	126.2	106.2
Prepayments made on inventories	7.9	19.3
Inventories	213.4	199.9